Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

View All

Sep 9, 2020 • 7:30 AM EDT

Rigel to Present at Two Upcoming Investor Conferences

Sep 2, 2020 • 7:30 AM EDT

Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference

Aug 4, 2020 • 4:01 PM EDT

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program

September 2020

View Presentation

Cantor Virtual Global Healthcare Conference

View Event View All

Q2 2020

Quarter Ended Jun 30, 2020

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080